Shared on 01 Nov 25
Fair value Increased 2.83%The analyst consensus price target for Taysha Gene Therapies has increased slightly from $9.50 to approximately $9.77, as analysts cite recent positive clinical milestone achievements, favorable FDA feedback, and an improved outlook for TSHA-102 in Rett syndrome. Analyst Commentary Bullish analysts remain highly positive on Taysha Gene Therapies following a series of milestone achievements and regulatory developments.
Shared on 17 Oct 25
Fair value Increased 0.88%FDA Meetings And TSHA-102 Trials Will Advance Approval
Analysts have increased their average price target for Taysha Gene Therapies to $9.50, up slightly from $9.42. Multiple firms cited the recent FDA breakthrough designation for TSHA-102, progress in pivotal trials, and perceived derisking of the program as key drivers of their positive outlook.
Shared on 03 Oct 25
Fair value Increased 13%FDA Meetings And TSHA-102 Trials Will Advance Approval
Taysha Gene Therapies’ analyst price target has increased from $8.32 to $9.42. Analysts point to recent FDA breakthrough therapy designation and progress in clinical studies as key drivers of heightened expectations.
Shared on 30 Jul 25
Fair value Increased 65%FDA Meetings And TSHA-102 Trials Will Advance Approval
Driven by promising early TSHA-102 clinical data in Rett syndrome, robust sales potential, and expected competition with Acadia's Daybue, analysts have raised Taysha Gene Therapies’ consensus price target from $5.04 to $8.32. Analyst Commentary Bullish analysts cite early data from TSHA-102 in Rett syndrome showing treated patients can gain or regain developmental milestones, distinguishing it from current therapies.
Shared on 01 May 25
FDA Meetings And TSHA-102 Trials Will Advance Approval
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 24 Apr 25
Fair value Decreased 7.01%FDA Meetings And TSHA-102 Trials Will Advance Approval
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.
Shared on 17 Apr 25
FDA Meetings And TSHA-102 Trials Will Advance Approval
AnalystConsensusTarget has increased revenue growth from 53.6% to 120.1%, decreased profit margin from 19.3% to 17.3% and decreased future PE multiple from 342.8x to 130.1x.
Shared on 09 Apr 25
FDA Meetings And TSHA-102 Trials Will Advance Approval
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 17%FDA Meetings And TSHA-102 Trials Will Advance Approval
AnalystConsensusTarget made no meaningful changes to valuation assumptions.